Ancrod in Acute Ischemic Stroke | Zendy

David E. Levy | Zendy; Gregory J. del Zoppo | Zendy; Bart M. Demaerschalk | Zendy; Andrew M. Demchuk | Zendy; HansChristoph Diener | Zendy; George Howard | Zendy; Markku Kaste | Zendy; Arthur Pancioli | Zendy; E. Bernd Ringelstein | Zendy; Carmen Spatareanu | Zendy; Warren W. Wasiewski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ancrod in Acute Ischemic Stroke

Author(s) -

David E. Levy,

Gregory J. del Zoppo,

Bart M. Demaerschalk,

Andrew M. Demchuk,

HansChristoph Diener,

George Howard,

Markku Kaste,

Arthur Pancioli,

E. Bernd Ringelstein,

Carmen Spatareanu,

Warren W. Wasiewski

Publication year - 2009

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.109.565119

Subject(s) - medicine , placebo , modified rankin scale , stroke (engine) , dosing , interim analysis , surgery , anesthesia , clinical trial , ischemic stroke , ischemia , mechanical engineering , alternative medicine , pathology , engineering

Previous studies of multiple-day dosing with the defibrinogenating agent, ancrod, in acute ischemic stroke yielded conflicting results but suggested that a brief dosing regimen might improve efficacy and safety. The Ancrod Stroke Program was designed to test this concept in subjects beginning ancrod or placebo within 6 hours of the onset of acute ischemic stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research